Market News How it works Learn FAQ
| RCT 0.1382 81.60% | NU 11.97 -21.04% | TGL 0.2617 18.15% | EWZ 32.715 -23.19% | SRTM 0.3394 -21.12% | BBD 2.835 -30.34% | SHFS 0.0989 -25.30% | GCDT 0.1322 -24.93% | ITUB 7.368 -23.81% | NWGL 0.0817 -0.37% | CLRO 4.67 43.69% | XP 14.8623 -51.13% | AZTR 1.265 76.92% | RBNE 0.1664 -12.42% | PBR 21.535 -17.68% | SGRY 23.055 46.38% | SOXL 85.96 2.87% | TSLL 10.8899 11.58% | SPCX 147.535 0.03% | VALE 12.0045 -3.19% | SPRC 1.4499 33.02% | NVD 4.04 -3.58% | CRWV 54.96 1.34% | JBLU 2.2085 -15.87% | SOXS 51.01 -2.76% | INTC 87.29 0.38% | GPUS 0.1679 -0.59% | NVDA 215 1.92% | TSLA 394.1 5.88% | IREN 24.64 -1.06% | ABEV 2.7991 -15.18% | TQQQ 67.83 2.32% | RENT 2.9899 30.00% | NOK 8.46 3.93% | INTR 4.415 -38.60% | PBR-A 18.92 -19.59% | XTND 2.8083 58.66% | SQQQ 38.76 -2.32% | BITO 10.6402 -1.75% | LUCD 0.5437 32.29% | SPDN 8.495 -0.53% | VBIO 0.8098 -13.85% | SBS 4.765 -25.55% | XXII 0.0999 -49.47% | SID 0.9233 -21.75% | STNE 7.96 -30.66% | KORU 10.6 0.19% | WFF 0.0765 -4.38% | RWM 14.4501 -0.69% | TSLG 5.45 11.91%
COCollegium Pharmaceutical, Inc. logo

Collegium Pharmaceutical, Inc. (COLL)

NASDAQ Global Select · Currency in USD
$23.38 ▲ +0.42 (+1.81%)
As of Oct 26, 11:20 AM ET. Market open.

Summary

Previous Close
$22.96
Open
$22.92
Day's Range
$22.92 – $23.42
52 Week Range
$21.43 – $50.79
Volume
81,020
Avg. Volume
702,773
Market Cap
$760.99M
Beta (5Y Monthly)
0.73
PE Ratio (TTM)
15.28
EPS (TTM)
$1.48
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$48.00

Profile: Collegium Pharmaceutical, Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
423
CEO
Vikram Karnani

Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $1.86 · Revenue est. $216.03M
DateEst.Actual
Aug 6, 2026$1.72$1.92Beat
May 7, 2026$1.52$1.76Beat
Feb 26, 2026$2.14$2.04Miss
Nov 6, 2025$1.86$2.25Beat
Aug 7, 2025$1.62$1.68Beat
May 8, 2025$1.43$1.49Beat

Analyst view

Consensus price target
$48.00 ▲ +105.3%
Range $45.00 – $50.00
Rating: Buy
Buy 67% · Hold 25% · Sell 8%

Similar stocks

Get free alerts on COLL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.